{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:13:32Z","timestamp":1784841212412,"version":"3.55.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bioorg.2025.108189","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T11:15:52Z","timestamp":1737371752000},"page":"108189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia"],"prefix":"10.1016","volume":"156","author":[{"given":"Zhuo","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ru","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Juan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Peng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108189_b0005","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.108189_b0010","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108189_b0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"issue":"2022","key":"10.1016\/j.bioorg.2025.108189_b0020","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"2010","key":"10.1016\/j.bioorg.2025.108189_b0025","first-page":"277","article-title":"Cancer statistics, 2010, CA Cancer","volume":"60","author":"Jemal","year":"2010","journal-title":"J. Clin."},{"key":"10.1016\/j.bioorg.2025.108189_b0030","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108189_b0035","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol.\/oncol. Clin."},{"key":"10.1016\/j.bioorg.2025.108189_b0040","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/leu.2009.49","article-title":"Bcr-Abl-mediated redox regulation of the PI3K\/AKT pathway","volume":"23","author":"Naughton","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.108189_b0045","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","article-title":"STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells","volume":"95","author":"Sillaber","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108189_b0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.108189_b0055","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995-2021): Medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0060","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108189_b0065","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108189_b0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trecan.2015.07.004","article-title":"The emerging role of ABL kinases in solid tumors","volume":"1","author":"Wang","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bioorg.2025.108189_b0075","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108189_b0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108189_b0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3324\/haematol.2019.219394","article-title":"Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening","volume":"105","author":"Outa","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2025.108189_b0090","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0095","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.108189_b0100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood.V128.22.625.625","article-title":"Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with CML-Chronic phase with failure of prior TKI therapy","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108189_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116678","article-title":"Targeting focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders","volume":"276","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116166","article-title":"Annual review of PROTAC degraders as anticancer agents in 2022","volume":"267","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0115","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: Expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108189_b0120","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/s41467-017-02313-6","article-title":"Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase","volume":"8","author":"Reckel","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108189_b0125","first-page":"117","article-title":"Structure of the Bcr-Abl oncoprotein oligomerization domain","volume":"9","author":"Zhao","year":"2002","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.bioorg.2025.108189_b0130","first-page":"447","article-title":"The ins and outs of bcr-abl inhibition, Genes","volume":"3","author":"Reddy","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.108189_b0135","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108189_b0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0092-8674(91)90148-R","article-title":"BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner","volume":"66","author":"Pendergast","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108189_b0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108189_b0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.108189_b0155","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(00)81883-8","article-title":"PI3K: Downstream AKTion blocks apoptosis","volume":"88","author":"Franke","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108189_b0160","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2025.108189_b0165","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia\u2013signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol.\/oncol. Clin. North Am."},{"key":"10.1016\/j.bioorg.2025.108189_b0170","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108189_b0175","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108189_b0180","doi-asserted-by":"crossref","first-page":"17967","DOI":"10.1073\/pnas.0808303105","article-title":"BCR-ABL-transformed GMP as myeloid leukemic stem cells","volume":"105","author":"Minami","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2025.108189_b0185","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","article-title":"Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation","volume":"26","author":"Coluccia","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2025.108189_b0190","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.108189_b0195","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108189_b0200","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","article-title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL","volume":"11","author":"Nardi","year":"2004","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bioorg.2025.108189_b0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.108189_b0210","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.108189_b0215","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40265-016-0677-x","article-title":"Dasatinib: A review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108189_b0220","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108189_b0225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.108189_b0230","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","article-title":"Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias","volume":"109","author":"Weisberg","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108189_b0235","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-642-01222-8_9","article-title":"Bosutinib","volume":"184","author":"Keller","year":"2010","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108189_b0240","first-page":"57","article-title":"Bosutinib: A SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia","volume":"6","author":"Rassi","year":"2013","journal-title":"Pharmgenomics Pers. Med."},{"key":"10.1016\/j.bioorg.2025.108189_b0245","first-page":"209","article-title":"Bosutinib: Pediatric first approval, Paediatr","volume":"26","author":"Hoy","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108189_b0250","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.108189_b0255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.108189_b0260","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"Global PROTAC toolbox for degrading BCR-ABL overcomes drug-resistant mutants and adverse effects","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.108189_b0270","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0275","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: First approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108189_b0280","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108189_b0285","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0290","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2019.08.007","article-title":"BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in philadelphia chromosome-positive leukemia","volume":"77","author":"Antelope","year":"2019","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bioorg.2025.108189_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105281","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease","volume":"108","author":"Walsh","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bioorg.2025.108189_b0300","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1182\/blood-2023-182343","article-title":"Tern-701 (HS-10382) is a potent inhibitor of BCR-ABL1 and is synergistic with active site tyrosine kinase inhibitors","volume":"142","author":"Parsons","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108189_b0305","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2022-162700","article-title":"Elvn-001, a next generation ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia","volume":"140","author":"Gross","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108189_b0310","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood-2023-185977","article-title":"Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric inhibitor in patients with tyrosine kinase inhibitor (TKI) resistant\/refractory chronic myeloid leukemia (CML): Preliminary results of phase I study","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108189_b0315","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14756366.2016.1250757","article-title":"Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance","volume":"32","author":"Lu","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0320","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/cmdc.201700829","article-title":"Alkynylnicotinamide-based compounds as ABL1 inhibitors with potent activities against drug-resistant CML harboring ABL1(T315I) mutant kinase","volume":"13","author":"Larocque","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.108189_b0325","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2017.06.001","article-title":"SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia","volume":"811","author":"Wang","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108189_b0330","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1158\/1538-7445.AM2019-1327","article-title":"Abstract 1327: UM-9107: A selective wild-type and T315I Bcr-Abl inhibitor with in vivo activity against chronic myelogenous leukemia","volume":"79","author":"Phadke","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108189_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112494","article-title":"Chimera induced protein degradation: PROTACs and beyond","volume":"206","author":"Yin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0345","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","article-title":"Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting Von hippel-lindau (VHL) E3 ubiquitin ligase","volume":"62","author":"Zhao","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0350","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108189_b0355","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1039\/D0CC02201B","article-title":"Scaffold hopping enables direct access to more potent PROTACs with in vivo activity","volume":"56","author":"Burslem","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bioorg.2025.108189_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113645","article-title":"Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation","volume":"223","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0365","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2025.108189_b0370","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: Novel light-controlled small-molecule tool for protein knockdown","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112894","article-title":"Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)","volume":"149","author":"Xia","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108189_b0380","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4056398","article-title":"The activity of novel BCR-ABL small-molecule degraders containing pyrimidine rings and their role in overcoming drug resistance","volume":"2022","author":"Zhang","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.bioorg.2025.108189_b0385","article-title":"Proteolysis targeting chimeras (PROTACs) based on imatinib induced degradation of BCR\u2010ABL in K562 cells","volume":"8","author":"Li","year":"2023","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.108189_b0390","doi-asserted-by":"crossref","first-page":"13549","DOI":"10.1038\/s41598-018-31913-5","article-title":"Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase","volume":"8","author":"Shibata","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108189_b0395","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1080\/14756366.2022.2074414","article-title":"Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents","volume":"37","author":"Wang","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0400","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1016\/j.bmcl.2016.09.041","article-title":"Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand","volume":"26","author":"Demizu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108189_b0405","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cas.13284","article-title":"Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands","volume":"108","author":"Shibata","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2025.108189_b0410","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/acsmedchemlett.7b00247","article-title":"Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation","volume":"8","author":"Shimokawa","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108189_b0415","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acschembio.0c00348","article-title":"A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL","volume":"15","author":"Tong","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108189_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104994","article-title":"Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML)","volume":"299","author":"Zhang","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108189_b0425","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","article-title":"Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16","volume":"15","author":"Zhang","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108189_b0430","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature18002","article-title":"Proteome-wide covalent ligand discovery in native biological systems","volume":"534","author":"Backus","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108189_b0435","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/jacs.1c03980","article-title":"Discovery of a covalent FEM1B recruiter for targeted protein degradation applications","volume":"144","author":"Henning","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.108189_b0440","first-page":"559","article-title":"Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function, Cell","volume":"28","author":"Luo","year":"2021","journal-title":"Chem. Biol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T01:55:34Z","timestamp":1758851734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825000690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":88,"alternative-id":["S0045206825000690"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108189","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108189"}}